In:
International Journal of Cancer, Wiley, Vol. 142, No. 12 ( 2018-06-15), p. 2578-2588
Abstract:
What's new? Cetuximab is an anti‐EGFR drug that is a valuable adjunct therapy for metastatic colorectal cancer (mCRC). Unfortunately, many tumors develop resistance. In this study, the authors found that a glutamine‐transporter protein called SLC1A5 is overexpressed in these resistant mCRC cells, and that blocking SLC1A5 activity restores the efficacy of cetuximab. These results support SLC1A5 as a promising therapeutic target for reversing cetuximab resistance.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8